Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avid Bioservices, Inc.

12.49
+0.0000
Volume:- -
Turnover:38.32M
Market Cap:798.90M
PE:-5.22
High:12.49
Open:12.49
Low:12.49
Close:12.49
Loading ...

Avid Recommends Stockholders Follow Recommendations of ISS and Glass Lewis and vote FOR the Transaction with GHO and Ampersand

GlobeNewswire
·
21 Jan

Lifecore Biomedical Announces Special Stockholder Meeting

GlobeNewswire
·
18 Jan

Scorpius Holdings Cancels Planned Reverse Stock Split

GlobeNewswire
·
18 Jan

Press Release: Scorpius Holdings Announces Reverse Stock Split

Dow Jones
·
17 Jan

HCW Biologics’ Founder and CEO to Address Opportunities and Challenges in Biomanufacturing for Cell and Gene Therapies During J.P. Morgan Week in San Francisco on January 15, 2025

GlobeNewswire
·
15 Jan

Press Release: Alcami Announces CEO Transition

Dow Jones
·
14 Jan

Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025

GlobeNewswire
·
13 Jan

Healios Expands ProcellCure Function to Include Contract Manufacturing Service

MT Newswires Live
·
13 Jan

Healios Expands ProcellCure’s Capabilities with CDMO Role

TIPRANKS
·
10 Jan

RBC Capital Sticks to Its Hold Rating for Avid Bioservices (CDMO)

TIPRANKS
·
10 Jan

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

GlobeNewswire
·
09 Jan

Press Release: Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand

Dow Jones
·
09 Jan

Press Release: Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million

Dow Jones
·
07 Jan

Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
07 Jan

EUROAPI welcomes the French Minister for Health and Access to Healthcare Yannick Neuder and the French Minister for Industry and Energy Marc Ferracci to its Puy-de-Dôme site

GlobeNewswire
·
07 Jan

Integer Holdings Corporation Announces Conversion Period for 2.125% Convertible Senior Notes due 2028

GlobeNewswire
·
03 Jan

Should You Retain Charles River Stock in Your Portfolio Now?

Zacks
·
02 Jan

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Business Wire
·
31 Dec 2024

Avid Bioservices' Waiting Period for Acquisition by GHO, Ampersand Expires

MT Newswires Live
·
30 Dec 2024

Avid Bioservices announces expiration of HSR waiting period for acquisition

TIPRANKS
·
30 Dec 2024